Amazon health-care threat? Teladoc CEO says it’s ‘overrated,’ but he should be worried
- Teladoc was a big stock market winner during the pandemic as medicine went virtual. However, the reopening and concerns about valuation and growth potential have pressured shares, down roughly 50% from its peak this year.
- It does not help that Amazon has set its sights on the health-care industry.
- Teladoc CEO Jason Gorevic isn’t worried about Amazon, saying the threat is “overrated,” but Wall Street analysts say there are questions about the company’s ability to grow into new care categories, along with better earnings and margins.
